CinCor Pharma Appoints Terry Coelho as Executive Vice President, Chief Financial Officer and Chief Business Development Officer
October 28, 2021 08:00 ET
|
CinCor Pharma, Inc.
CINCINNATI, Oct. 28, 2021 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) today announced the appointment of Terry Coelho as Executive Vice President, Chief Financial Officer and Chief Business...
CinCor Pharma Appoints Mason Freeman, M.D., as Executive VP, Clinical Development
October 19, 2021 08:00 ET
|
CinCor Pharma, Inc.
CINCINNATI, Oct. 19, 2021 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) today announced the appointment of Mason W. Freeman, M.D., as Executive Vice President, Clinical Development responsible...
CinCor Pharma Raises $143 Million in Series B Financing
October 12, 2021 08:00 ET
|
CinCor Pharma, Inc.
Funding will support continued development of CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase product candidate, for the treatment of hypertension, primary...
CinCor Pharma Appoints Marc de Garidel as Chief Executive Officer
July 06, 2021 08:00 ET
|
CinCor Pharma, Inc.
CINCINNATI, July 06, 2021 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) today announced the appointment of Marc de Garidel, currently on the Company’s Board of Directors, as Chief Executive...
CinCor Pharma Announces Appointments of Three Experienced Independent Members to Its Board of Directors
May 20, 2021 08:00 ET
|
CinCor Pharma, Inc.
Experienced biopharmaceutical executive, John F. Thero, Chief Executive Officer of Amarin Corporation PLC, a commercial-stage cardiovascular companySeasoned biopharmaceutical finance executive, Troy...
CinCor Pharma Announces First Patient Dosed with CIN-107 in Phase 2 Study in Treatment Resistant Hypertensive Subjects
October 20, 2020 08:00 ET
|
CinCor Pharma, Inc.
CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company developing medications targeting cardiovascular disease, announced today that...
CinCor Pharma In-Licenses Aldosterone Synthase Inhibitor, CIN-107, and Closes $50 Million Series A Financing
May 14, 2019 08:00 ET
|
CinCor Pharma, Inc.
CINCINNATI, May 14, 2019 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) announced today that it has signed an agreement with Roche to acquire exclusive global rights to a novel aldosterone...